CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

About this update from Camp4 Therapeutics Corporation

Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the closing of the second tranche of its previously announced private placement pursuant to a securities purchase agreement, dated September 9, 2025, with certain institutional and accredited investors. In connection with the second closing, the Company received approximately $50.1 million in gross proceeds in exchange for 10,756,498 shares of common stock priced at $1.53 per share of common stock, 39,306 shares of common stock priced at $1.65 to certain directors, employees and consultants of the Company, and 21,925,368 pre-funded warrants in lieu of common stock for $1.5299 for each pre-funded warrant sold in lieu of common stock. The Company intends to use the net proceeds from the private placement to support the continued advancement of CMP-002, for which the Company recently announced it had received clearance from Australia's Therapeutic Goods Administration and local Human Research Ethics Committee to initiate a Phase 1/2 clinical trial in SYNGAP1-related disorder, as well as to support the continued development of the Company's early-stage pipeline. Investors that participated in the second closing include Coastlands Capital, Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management LP, Trails Edge Capital Partners and CURE SYNGAP1. Leerink Partners acted as lead placement agent in connection with the second closing. Piper Sandler & Co., Cantor Fitzgerald & Co. and Wedbush Securities Inc. acted as co-placement agents. The securities offered in the private placement, including the shares underlying the pre-funded warrants, were sold in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or under any applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the...

View stock analysis, news, and events for Camp4 Therapeutics Corporation